Loading news...
Bioventus Inc. (BVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET).
Bioventus (NYSE: BVS - Get Free Report) and Medifocus (OTCMKTS:MDFZF - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability. Earnings and Valuation This table compares Bioventus and Medifocus"s
Bioventus Inc. (NYSE: BVS - Get Free Report)'s stock price traded down 1.1% on Tuesday. The stock traded as low as $7.34 and last traded at $7.45. 291,511 shares were traded during trading, a decline of 21% from the average session volume of 369,373 shares. The stock had previously closed at $7.53. Bioventus Trading Down
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders.
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Wednesday, December 3, 2025, at 10:10 a.m. ET.
Bioventus Inc. ( BVS ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Presentation Operator Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 27, 2025.
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. If you currently own Bioventus stock and acquired shares on or before February 11, 2021, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn mor.
Bioventus Inc. (NASDAQ:BVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst Thanks, everyone, for joining us. Before we begin, just the disclaimer.
DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET.
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET.
Bioventus Inc. (NASDAQ:BVS ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senior VP & CFO Robert E.
Bioventus (BVS) came out with quarterly earnings of $0.21 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.19 per share a year ago.
DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 28, 2025.
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the “Credit Agreement”) consisting of a $300 million term loan facility and a $100 million revolving credit facility on July 31, 2025. The new Credit Agreement will mature on July 31, 2030.